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ABSTRACT
Objective: The spine is the most common location for bone metastases. 
Since cure is not possible, local control and relief of symptoms is the 
basis for treatment, which is grounded on the use of conventional 
radiotherapy. Recently, spinal radiosurgery has been proposed for 
the local control of spinal metastases, whether as primary or salvage 
treatment. Consequently, we carried out a literature review in order 
to analyze the indications, efficacy, and safety of radiosurgery in the 
treatment of spinal metastases. Methods: We have reviewed the 
literature using the PubMed gateway with data from the MEDLINE 
library on studies related to the use of radiosurgery in treatment 
of bone metastases in spine. The studies were reviewed by all the 
authors and classified as to level of evidence, using the criterion 
defined by Wright. Results: The indications found for radiosurgery 
were primary control of epidural metastases (evidence level II), 
myeloma (level III), and metastases known to be poor responders to 
conventional radiotherapy – melanoma and renal cell carcinoma (level 
III). Spinal radiosurgery was also proposed for salvage treatment after 
conventional radiotherapy (level II). There is also some evidence as to 
the safety and efficacy of radiosurgery in cases of extramedullar and 
intramedullar intradural metastatic tumors (level III) and after spinal 
decompression and stabilization surgery. Conclusion: Radiosurgery 
can be used in primary or salvage treatment of spinal metastases, 
improving local disease control and patient symptoms. It should also 
be considered as initial treatment for radioresistant tumors, such as 
melanoma and renal cell carcinoma.
Keywords: Radiosurgery; Neoplasm metastasis/therapy; Spinal neoplasms/ 
radiotherapy
RESUMO
Objetivo: A coluna vertebral é o local mais comum de metástases 
ósseas. Uma vez que a cura não pode ser obtida, o controle local e o 
alívio dos sintomas é a base do tratamento, sendo este fundamentado 
no uso de radioterapia convencional. Recentemente, a radiocirurgia 
espinhal foi proposta para o controle local das metástases na coluna, 
seja como tratamento primário ou de resgate. Dessa forma, realizamos 
uma revisão da literatura para analisar as indicações, a eficácia e a 
segurança da radiocirurgia no tratamento das metástases da coluna. 
Métodos: A revisão de literatura foi realizada no portal PubMed – 
dados da biblioteca MEDLINE, sobre os estudos relacionados ao 
uso da radiocirurgia no tratamento para metástases ósseas na 
coluna vertebral. Os estudos foram revisados por todos os autores 
e classificados quanto ao nível de evidência, utilizando critério 
definido por Wright. Resultados: As indicações encontradas para 
radiocirurgia foram: controle primário de metástases epidurais (nível 
II de evidência), mieloma (nível III) e metástases sabidamente pouco 
responsivas à radioterapia convencional – melanoma e carcinoma de 
células renais – (nível III). A radiocirurgia espinhal também foi proposta 
para o tratamento de resgate após falha da radioterapia convencional 
(nível II). Existe ainda alguma evidência quanto à segurança e a 
eficácia da radiocirurgia em casos de tumores metastáticos intradurais 
extramedulares e intramedulares (nível III), e após cirurgias de 
descompressão e estabilização da coluna. Conclusão: A radiocirurgia, 
portanto, pode ser usada no tratamento primário ou de resgate de 
metástases espinhais, melhorando o controle local da doença e dos 
sintomas dos pacientes. Deve ainda ser considerada como tratamento 
inicial para tumores radiorresistentes, como melanoma e carcinoma de 
células renais.
Descritores: Radiocirurgia; Metástase neoplásica/terapia; Neoplasias 
da coluna vertebral/radioterapia
INTRODUCTION
The spine is the most common site for bone metastases(1). 
Spinal involvement occurs in up to 40% of patients with 
cancer during progression of the disease, with 5 to 10% of 
these patients developing epidural compression at some 
point of their progression(2). More than 90% of the spinal 
metastases are located extradurally, whereas about 5% 
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are intradural and less than 1% are intramedullar(3). 
Symptomatic compression occurs more frequently in 
the thoracic spine (50 to 70%), followed by the lumbar 
spine (20 to 30%) and the cervical spine (10 to 30%)(4). 
This probably occurs because the thoracic canal has the 
smallest diameter and the largest number of vertebrae 
in the spine. The posterior half of the vertebral body 
is the most commonly involved(4), spreading latterly to 
other regions (anterior body, lamina, and pedicles). 
Also important is the fact that by the time of diagnosis, 
multiple lesions can be found at noncontiguous levels 
in up to 40% of the patients. Regarding histology, up 
to 50% of the metastases come from one of the three 
following cancers: breast, lung, or prostate(1).
Since spinal metastases suggest a non-controlled 
tumor, treatment is mainly based on palliation and local 
disease control. Although in selected cases chemotherapy 
can be used, radiotherapy, with or without concomitant 
surgery, remains the main treatment modality(5,6). 
Surgical techniques have progressed substantially in 
the last years, allowing circumferential decompression 
of the spinal cord and spinal fixation for early 
stabilization(6). The main goals of surgery are spinal 
stabilization, restoration, and maintenance of the global 
alignment and decompression of neural structures, 
especially in radioresistant tumors(5). Surgery can 
also be an option in unknown primary tumors (when 
a tissue sample is necessary) or in cases where local 
pain persists after other treatment modalities have 
been used. However, the surgical option should only be 
considered for patients with good performance scores, 
since it may entail serious morbidity and possible 
medical complications. Prognostic scoring systems, like 
the one proposed by Tokuhashi et al. and Tomita et al., 
are useful in surgical decision-making(7,8).
Role of radiation therapy in spinal metastases
Since surgery is only considered in selected cases, 
conventional external beam radiotherapy (CER) remains 
the mainstay treatment modality for spinal metastases. 
The total dose of radiation ranges from 25 to 40Gy, 
fractionated daily into 8 to 20 doses(6). A broad margin 
is used in the radiation field, typically one or two 
vertebral segments above and two segments below 
the affected level in order to compensate for internal 
vertebral motion. This technique exposes healthy tissue 
to radiation, including the sensitive spinal cord. The 
dose of radiation is fractioned to allow recovery of the 
normal tissue, thus improving tolerance(6).
Spinal stereotactic radiosurgery (SRS) is a more 
recently developed type of radiation therapy that delivers 
a high dose of radiation to the tumor, whilst minimizing 
the amount delivered to the healthy neighboring tissues. 
The target is defined by high-resolution stereotactic 
imaging, and requires rigid spine immobilization to 
offer a precise conformal dose, using frame or frameless 
techniques, based on external immobilization devices 
with fiducial markers. Treatment is fractionated into 
fewer sessions (one to five), with total doses ranging 
from 8 to 30Gy. When one session is used, the term 
“radiosurgery” must be preferentially used, whereas 
“fractionated stereotactic radiosurgery” is better used 
when multiple sessions are performed. Early versions of 
SRS in the spine required surgical fixation of frames in 
the spinous processes to avoid movement artifacts. The 
novel systems are frameless, based on internal skeletal 
anatomy, and implanted fiducial points, or infrared 
surface markers, with near real-time images for motion 
correction. Radiation intensity modulation increases the 
conformity of radiation to the tumor, minimizing the dose 
to normal tissue(6). However, the effectiveness, safety, 
precise indications, and long-term evaluation regarding 
disease control of the effects of SRS remain unclear. 
OBJECTIVE
To perform a literature review of the indications, safety, 
and efficacy of spinal radiosurgery when compared to 




A literature review using the PubMed gateway of 
the MEDLINE database was performed, with no 
time restriction, until September, 2012. The following 
key-words were queried, singly or in combination: 
“radiosurgery”, “stereotactic”, “spinal metastases”, 
“spinal cancer”, “treatment”, “indications”, “radiation 
therapy”, and “extracranial”.
Study selection 
We included clinical papers of patients who received 
radiosurgery for the treatment of spinal metastases.
We excluded non-English language papers, literature 
reviews, case reports, and papers not focused on 
radiosurgical treatment of spinal metastases.
Data extraction
One hundred and twenty-four studies were reviewed 
and scrutinized according to study design (retrospective 
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case series, prospective studies, and randomized control 
trials), patient characteristics, and primary findings by 
four independent researchers (AFJ, EG, HT, LG). 
After analysis of the four authors, reselection was made 
and a total of 31 studies were selected and included in 
our review.
Measurements and outcome evaluation
The results of the studies were grouped according to 
their main purpose: pain control, radiological control, 
overall survival, comparison of treatment modalities 
(SRS versus CER versus surgery), indications for spinal 
radiosurgery, and methods of evaluating disease control 
and response to treatment.
Evaluation of the level of evidence
The studies were classified according to the level of 
evidence for therapeutic studies, defined by Wright et al.(9). 
1.  Higher quality randomized controlled trial.
2. Lesser quality randomized controlled trial; prospective 
comparative study.
3.  Case-control study; retrospective comparative study.
4.  Case series.
5.  Expert opinion.
RESULTS
Out of 31 selected studies, a total of 2,241 patients 
were treated for spinal metastases. All papers are 
summarized on chart 1.
Chart 1. Selected studies after a systematic review using the MEDLINE database
Study type Radiosurgery status/indication n Dose Results
Ahmed et al.(10) Prospective 
case series
Primary and 
reirradiation therapy for 
spinal metastases
66 patients (85 
lesions)
24Gy (10-40Gy) 
(median 3 fractions, 
range to 1-5)
The mean actuarial survival at 12 months was 52.2%
7 patients had both local and marginal failure, 1 patient experienced 
marginal but not local failure, and 1 patient had local failure only
Actuarial local control at 1 year was 83.3% and 91.2% in patients with 
and without prior RT, respectively
No Grade 4 toxicities were reported
Amdur et al.(11) Prospective 
case series
Primary and 
reirradiation therapy for 
spinal metastases
21 patients (9 
patients; no prior 
radiotherapy and 12 
patients with prior 
radiotherapy)
15Gy (no prior spinal 
radiotherapy)
5Gy (prior spinal 
radiotherapy)
No late toxicities
3 patients experienced radiographic evidence of vertebral body 
compression in field
43% experienced pain relief
1-year progression-free survival was 5% with 60% of patients dead 
by 1 year
In patients with and without prior radiotherapy, they achieved the 
target-coverage goal in 91% and 95%, respectively
Benzil et al.(12) Case series Primary and 
reirradiation therapy for 
spinal metastases and 
primary tumors
31 patients (35 
lesions); 26 
metastases and 
4 intradural and 5 
extradural tumors
Mean single dose 
2.68Gy and mean 
total dose 6.89Gy for 
intradural tumors
Significant pain relief was achieved in 32/34 treated tumors
Pain relief was achieved with a single dose as low as 5Gy
2 patients experienced transient radiculitis (both with a BED >60Gy)
No patient experienced other organ toxicity
Chang et al.(13) Case series Primary radiosurgery 
for spinal metastases
63 patients 27-30Gy (three 9Gy 
fractions and five 6Gy 
fractions) 
No neurological complications (median of 21.3 months of follow-up)
1-year tumor progression-free was 84%
Mild symptoms of toxicity (nausea, vomiting, and diarrhea)
Chang et al.(14) Case series Primary and 
reirradiation therapy for 
spinal metastases
129 patients (53 
reirradiation)
16-39Gy in 1-5 
fractions
Pain relief in 91%
In 108 lesions, 75 decreased or stable mass size
Chang et al.(15) Case series Primary and 
reirradiation therapy for 
spinal metastases
54 retreatment and 
131 initial SBRT
Mean radiation 
doses to tumor 
margin 51.1Gy 2/10 
(retreatment) and 
50.7Gy 2/10 (initial 
treatment)
Mean progression-free period was 23.9 months (overall); 18 months 
(retreatment) and 26 months (initial treatment)
Radiological control rates were about 95% at 6 months and up to 
80% at 12 months
No radiation myelopathy
De Salles et al.(16) Case series Radiosurgery for spinal 
metastases and benign 
spinal tumors
14 patients (22 
lesions); 11 patients 
with metastases, 2 
neurofibromas, and 1 
meningioma
A mean dose of 
12±2.7Gy (range 
8-21Gy)
x 13 received single-
dose stereotactic 
radiosurgery
Mean follow-up period was 6.1±3.9 months (range 1-16 months)
3 patients became pain-free and 4 experienced considerable relief
Weakness improved in 2 patients with this preoperative symptom and 
the asymptomatic patients remained asymptomatic
4 lesions decreased in size, 5 remained stable, 7 progressed, and 6 
were not followed (2 patients died before follow-up)
4 patients in all died, 3 of systemic disease and 1 of thoracic lesion 
progression
No complications were observed
Continue...
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Chart 1. Selected studies after a systematic review using the MEDLINE database
Study type Radiosurgery status/indication n Dose Results








Mean follow-up of 20 months
Actuarial 18-month imaging local control rate for all patients was 88%
Actuarial 18-month overall survival rate for all patients was 64% with a 
median survival for all patients of 30 months
No significant differences in outcomes were noted with respect to tumor 
histology or dose
The data support an expanded indication for spinal radiosurgery as first-
line treatment 
Levine et al.(18) Case series Primary radiosurgery 





30Gy 7 patients definitively treated; 2 complete regression, 3 partial regression, 
and 2 late recurrence re-treated
7 had surgery + SRS; 5 cases of total tumor control with mean follow-up 
of 43.5 months





Case series Primary (14 lesions) or 
metastatic (39) spinal 
lesions




Median follow-up of 11.1 months
59% of patients experienced no acute side effects from treatment; there 
were 3 cases of acute grade 3 toxicity
Local control and overall survival were 91 and 65%, respectively
Pain improvement was seen in 75% of symptomatic metastases at 6 
months post-treatment
Patel et al.(20) Case series Primary irradiation of 
spinal metastases 




(W) versus partial (P) 
contour approach of 
the vertebral body
W Group had a lower re-treatment rate (11% for W Group versus 18.6% 
for P Group; p=0.285)
Prior surgery status (β=1.953; OR=7.052; p <0.001) was correlated to 
the re-treatment rate
The 2-year survival was 25.7% in W Group and 20.9% in P Group (p=0.741)
They concluded that contouring the whole vertebral body for stereotactic 
body radiation therapy treatment of metastatic spinal lesions shows 
potential benefits by reducing the risk of recurrence, improving 
symptomatic relief, and providing improved local tumor control
Ryu et al.(21) Case series Primary radiosurgery 
for spinal metastases




Complete/partial relief in 85%
Relapse of pain in 7%
5% of radiologically adjacent spine metastases 
Wang et al.(22) Case series Primary irradiation of 
spinal metastases




Median follow-up of 15.9 months
Pain control improved from 26-54% at 6 months
Progression-free survival after SBRT was 80.5% at 1 year
Gerszten et al.(23) Case series Primary and 
reirradiation therapy 
for renal cell carcinoma 
metastases
48 patients with 60 
RCC metastases 
(42 lesions were 
reirradiated)
Tumor dose range 
to 17.5-25Gy  
(mean 20Gy);  
single dose
Follow-up for 14-48 months (median 37 months)
No radiation-induced toxicity occurred during the follow-up period
Axial and radicular pain improved in 34 (89%) of 38 patients who were 
treated primarily for pain
Tumor control was demonstrated in 7 of 8 patients treated primarily for 
radiographically documented tumor progression
6 patients required open surgical intervention for tumor progression that 
had caused neurological dysfunction after radiosurgery
Gerszten et al.(24) Case series Primary and 
reirradiation therapy 
for melanoma spinal 
metastases
28 patients (36 




 Maximum dose  
was 17.5-25Gy  
(mean 21.7Gy);  
single fraction
Follow-up period of 3-43 months (median 13 months)
No radiation-induced toxicity occurred during the follow-up period
Axial and radicular pain improved in 27 of 28 patients (96%) who were 
treated primarily for pain
Long-term tumor control was seen in 3 of 4 cases treated primarily for 
+ tumor progression. Two patients went on to require open surgical 
intervention for tumor progression resulting in neurological deficit
Choi et al.(25) Case series Reirradiation therapy 
for spinal metastases 
(median previous spinal 
cord dose of 40Gy)
42 patients (51 
lesions)
Median dose of  
20Gy  
(range 10-30Gy) in  
1-5 fractions  
(median 2)
Median follow-up of 7 months (range: 2-47 months)
The Kaplan-Meier local control and overall survival rates at 6/12 months 
were 87%/73% and 81%/68%, respectively
Time to re-treatment of ≤12 months and the combination of time to re-
treatment of ≤12 months with an SSED of <15Gy ( 10) were significant 
predictors of local failure on univariate and multivariate analyses
1 patient (2%) experienced Grade 4 neurotoxicity
Continue...
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Chart 1. Selected studies after a systematic review using the MEDLINE database
Study type Radiosurgery status/indication n Dose Results




for breast cancer spinal 
metastases




18 who received 
conventional RDP
Doses ranging  
from 21-28Gy  
(3-5 fractions)
Both groups were comparable along all matching dimensions and in 
performance status before treatment
Outcomes of treatment were similar for patients in both groups; 
ambulation, performance status, and pain worsened similarly across 
groups post-treatment
Survival and the number of complications appeared to favor the 
CyberKnife group, but the differences did not reach statistical 
significance
Salvage CyberKnife is efficacious





58 patients Adjacent level disease 
after irradiation of the 
involved vertebral body
Avoid the historic irradiation of 1-2 vertebral bodies above/below the 
involvement using EBRT
Multiple level of SRS irradiation is unnecessary
3% of failure compared with <5% of isolated failures of the 
unirradiated adjacent vertebral body
Koyfman et al.(28) Case series Reirradiation for 
previously irradiated 
spinal metastases
149 patients (208 
lesions)
14Gy  
(median dose  
ranging from 10-16Gy)
Median follow-up was 8.6 months, and median survival was 12.8 months
Recurrence occurred in 26 (12.5%) treated lesions, at a median time 
of 7.7 months after conventional radiotherapy
Patients with paraspinal disease at the time of conventional 
radiotherapy (20.8% versus 7.6% of patients; p=0.02), and those 
treated with <16Gy (16.3% versus 6.3% of patients; p = 0.14) had 
higher rates of recurrence
Mahadevan et al.(29) Case series Reirradiation for 
previously irradiated 
spinal metastases
60 patients 8Gy ×3=24Gy  
(far from the cord)  
5 to 6Gyx5=25 to 30Gy 
(near the cord)
9 months median progression-free survival
93% had stability
65% had pain relief
7% disease progression
No toxicity
Nikolajek et al.(30) Case series Reirradiation for 
previously irradiated 
spinal metastases
54 patients (70 
lesions) 
Median radiosurgery 
dose: 1 × 18Gy  
(range 10-28Gy) to the 
median 70% isodose 
single fraction 
Median follow-up of 14.5 months
The actuarial rates of freedom from local failure at 6/12/18 months 
were 93%, 88%, and 85%, respectively
In 6 out of 7 patients worse sensory or motor deficit after SRS was 
caused by local or distant failures (diagnosed by CT/MRI)
1 patient with metastatic renal cell carcinoma developed a progressive 
complete paraparesis 1 year after the last treatment at lumbar level L3




39 patients (60 
lesions)
23 lesions were 
unirradiated
37 were reirradiated 
(31 had image tumor 
progression)
Median total dose 
prescribed was 24Gy  
in 3 fractions
Median survival time measured was 21 months (95%CI=8-27 months).
2-year survival probability was 45%
Median tumor follow-up for the unirradiated and reirradiated group 
was 9 months (range: 1-26) and 7 months (range: 1-48) respectively
8 of 60 tumors have progressed, and the 1- and 2-year PFP was 85% 
and 69%, respectively
For the salvage group the 1-year PFP was 96%
In 6 of 8 failures the minimum distance from the tumor to the thecal 
sac was <or=1mm
39/60 had >or=6 months follow-up and no radiation-induced myelopathy 
or radiculopathy occurred
Sahgal et al.(32) Case series Reirradiation for 
previously irradiated 
with external beam 
radiation
19 patients (5 with 
radiation myelopathy 
- RMI and 14 without 
it - no-RMI)
Mean of 20Gy in the 
no-RMI group versus 
1-5 fractions 67.4  
in the RMI group
SBRT given at least 5 months after conventional palliative radiotherapy 
with a reirradiation dose of 20-25Gy (2/2) appeared to be safe, 
provided the total dose does not exceed approximately 70Gy (2/2)
Sheehan et al.(33) Case series Spinal radiosurgery 
using a helical 
Tomotherapy
40 patients (110 
tumors); range 1-6 
tumors per patient
23 (57.5% underwent 
previous surgery
Mean radiosurgical 
dose was 17.3Gy 
(range: 10-24Gy)
Mean follow-up duration of 12.7 months (range: 4-32 months)
Decreased or stable tumor volume was seen in 90 (82%) of the 
tumors treated
Pain improvement in 34 patients (85%)



















81% had complete radiographic response
86% pain control
71% of improvement in neurological symptoms
Continue...
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Indications
Primary radiosurgery for treatment of epidural spinal 
metastases was reported in 13 studies, including spinal 
sarcomas. These studies were classified as level II 
and level III of evidence(10-22). Two studies reported 
the efficacy and safety of radiosurgery in tumors with 
known low response to CER, and radioresistant tumors 
such as melanoma and renal cell carcinoma(23,24).
SRS as salvage treatment, after failure of previously 
irradiated epidural spinal metastases with CER, was 
reported in 15 studies(10-12,14,15,19,25-33) (levels II and III).
The use of spinal radiosurgery for treatment of 
intradural extramedullary and intramedullary spinal 
metastases and for epidural compression of myeloma 
was reported in one study each (level III)(34,35).
Radiosurgery following surgery for decompression 
and stabilization was reported in three studies (level 
III)(33,36-37).
Dose intensity and number of fractions
The dose obtained in the studies for epidural metastases 
ranged from 8 to 30Gy (different low doses were used for 
intradural tumors)(12), in one to five fractions. Moulding 
et al. considered that when lower doses were used (18 to 
21Gy), worse local control was obtained compared to 
higher doses (18-24Gy). Some authors administered the 
same doses for all patients(18), whereas others reported 
that factors such as prior conventional radiotherapy, 
distance of the epidural metastases from the cord(29), 
...continuation
Chart 1. Selected studies after a systematic review using the MEDLINE database
Study type Radiosurgery status/indication n Dose Results
Massicote et al.(36) Case series Primary irradiation 
after minimally 
invasive spinal surgery 
for unstable spinal 
metastases
10 patients 8 patients were symptomatic at baseline
The median follow-up was 13 months (range: 3-18)
Following surgery, the median time to SBRT treatment 
planning was 6.5 days and subsequent median time to 
treatment was 7 days
Local control was observed in 7 of the 10 patients. 
Improvements in VAS, ODI, and QOL were observed post-
SBRT
Moulding et al.(37) Case series Surgical 
decompression and 









18-24Gy (median 24) 
single dose
Planned target volume 
received a high dose 
(24Gy) in 16 patients 
(76.2%), and a low 
dose (18 or 21Gy) in  
5 patients (23.8%)
15 (72%) of 21 patients died, and in all cases death was due to 
systemic progression as opposed to local failure
The median overall survival after radiosurgery was 310 days
One patient (4.8%) underwent repeat surgery for local failure 
and 2 patients (9.5%) underwent spine surgery for other 
reasons
Local control was maintained after radiosurgery in 17 (81%) 
of 21 patients until death or most recent follow-up, with an 
estimated 1-year local failure risk of 9.5%
Of the failures, 3 of 4 were noted in patients receiving low-
dose radiosurgery
Patients receiving adjuvant stereotactic radiosurgery with 
a high dose had a 93.8% overall local control rate (15 of 16 
patients), with a 1-year estimated failure risk of 6.3%







30Gy (5 fractions; 6Gy)
27Gy (3 fractions; 9Gy)
1-year overall survival in 76% with local control
92% freedom from neurological injury
81% of the tumors within 5mm of the spinal cord developed 
cord compression






500 cases  Maximum intratumoral 
dose range from 
12.5-25Gy (mean 20Gy) 
(single fraction)
Long-term pain improvement occurred in 290 of 336 cases 
(86%)
Long-term tumor control was demonstrated in 90% of lesions 
treated with radiosurgery as a primary treatment modality and 
in 88% of lesions treated for radiographic tumor progression
27 of 32 cases (84%) with a progressive neurologic deficit 
before treatment experienced at least some clinical 
improvement
Haley et al.(40) Prospective case 
series
Compare the efficacy 
and cost effectiveness 
of EBRT versus SRS
 44 (22 received EBRT 
and 22 SRS)
EBRT cost 29-71% of the SRS treatment, had more acute 
toxicity (but self-limited and with low grade), and more of 
them need further intervention (surgery/kyphoplasty)
No late complication in either groups
Similar pain relief
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and tumor histology(23), among others, were used to 
individualize the dose. It also should be mentioned that 
lower doses were used for intradural and intramedullar 
metastases as well as for salvage treatment after prior 
conventional radiotherapy, in order to avoid late 
radiation myelopathy.
Pain control
Although the lack of standardized outcome measurements 
in the reviewed studies precluded deep or statistical 
analyses, pain was substantially controlled (up to 90%) in 
many series, suggesting good efficacy in decreasing pain 
symptoms(10-12,14,16,19,23,24,29,33,35,38,39). A potential advantage 
of SRS is the time required to obtain some pain 
relief, as early as 24 hours, probably quicker than 
CER(21). However, it is important to emphasize that 
the methods utilized for pain evaluation in different 
papers were very heterogeneous, which precluded a 
uniform analysis (verbal analysis scale, and subjective 
measurements of pain relief, among others). In 
some tumors considered radioresistant to CER, pain 
control was achieved in 96% of the patients with 
melanomas and in 89% of the patients with renal cell 
carcinoma(23,24). However, we also observed that low 
rates of pain control (43%) were obtained in a series 
using a lower dose of SRS(11).
Toxicity
Radiation-related toxicity was mild in almost all series, 
with rare reports of severe toxicity(10,12-13,29,31). Transient 
radiculitis was reported in 2 of 31 patients of the 
Benzil et al. series(12). Three patients of 41 in the cases 
published by Martin et al. presented with toxicity grade 
3(19). These rarely reported cases of moderate toxicity 
in all the cases reviewed suggested that SRS is a safe 
procedure. 
Local disease control 
The efficacy of spinal radiosurgery in local disease 
control was assessed clinically and radiologically in 
some studies. Chang et al. reported radiological control 
of spinal metastases in 90% of the patients at 6 months 
and in 80% at 12 months, similar to Garg et al., who 
obtained an imaging control rate of 88% of the patients 
after 18 months of follow-up(15,17). Sheehan et al.(33)
also reported decreased or stable tumor volume in 
82% of the patients treated (mean of 12.7 months of 
follow-up). Some papers also reported improvement in 
neurological deficits after treatment with SRS(16,25,39).
Regarding tumor recurrence, some interesting 
information was obtained: Koyfman et al. reported 
that the presence of paraspinal disease at the time 
of CER (prior to SRS) was associated with high 
rates of local recurrence (p=0.02)(28). A dose lower 
than 16Gy was also associated with local recurrence 
(p=0.14). Regarding the radiation target, Klish et al. 
evaluated a prospective series of 58 patients with good 
disease control and no damage to healthy tissues, and 
concluded that irradiation one or two levels above or 
below the involved segment is not necessary when SRS 
is performed(27). 
Cost-effectiveness of CER versus SRS
In one prospective case series, Haley et al.(40) compared 
the efficacy/cost- effectiveness of CER versus SRS. At 
1-month follow-up, they reported that both methods 
have similar outcomes regarding pain relief, but CER 
costs about 29 to 71% less than the SRS treatment. 
However, CER has a high rate of acute toxicity (although 
it was self-limited and with low intensity) and required 
more interventional procedures (surgery, kyphoplasty 
etc.) at the level of the treated spinal. Neither method 
had late complications. 
DISCUSSION 
The ideal treatment of spinal metastases would be one 
that obtains cure without adding excessive morbidity. 
However, since no treatment has been proven to increase 
life expectancy, the main objectives of treatment remain 
local disease control, pain relief, reestablishment of 
a normal neurological status, and avoidance of spinal 
deformity/instability. Surgery is reserved for an unstable 
spine, to obtain tissue samples, for pain relief in cases 
of instability, or for urgent decompression. Regardless 
of the indication for initial surgical treatment, almost 
all patients should be referred to radiation therapy 
treatment.
As shown in our data, SRS was efficient in controlling 
pain in many series(10-12,14,16,19,23,24,29,33,34,38,39). Most of the 
studies showed pain control of up to 90%, even for 
radioresistant tumors such as melanomas and renal cell 
carcinoma. Since a cure is not possible, the palliative 
effect of SRS in pain control has been one of the main 
reasons for radiation treatment in these patients. 
Clinical stability and radiological disease control 
were obtained in up to 95% of the series(15,17,33). The 
efficacy of local control decreased with time, but most 
of the patients died from progression of the systemic 
disease before local recurrence(37). The presence of 
paraspinal disease increases local recurrence probably 
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because it is associated with late stages of cancer and a 
more systemic disease. This radiological control obtained 
with SRS can decrease or stabilize tumor volume, 
improving the neurological status in some series(16,35,39). 
All these features confirm SRS as an efficient method 
for treating spinal metastases regarding local control. 
Ideally, an efficient method that improves the 
patient’s symptoms should not carry high morbidity 
rates. In this context, the studies assessed in our review 
with more than 2,000 patients did not demonstrate 
severe toxicity related to SRS. Moreover, when reported, 
toxicity was mild and self-limited, attesting to the safety 
of SRS in treatment of spinal cancer(10,12,13,29,32).
Since safety and efficacy are warranted, the oncology 
group needs to individualize the patient’s treatment 
and decide between SRS and CER. Although both 
methods require certainty of the diagnosis, SRS has its 
best indications for patients with more restricted spinal/
paraspinal metastases (involving one to two spinal 
segments); on the other hand, CER is more efficient for 
multiple level spinal involvement(34). As stated before, 
although costs favor the indication of CER(40), this 
assertion does not really reflect the truth, especially for 
patients who live far from radiotherapy centers, as SRS 
requires less fractions (1 to 5) compared to CER (8 to 
20 daily fractions).
Although many questions are not yet solved, SRS has 
proven to be an efficient and safe alternative to CER for 
treating patients with restricted spinal metastases. The 
best indication for using SRS as a primary treatment 
of spinal metastases is likely for disease restricted to 
one or two levels of a known poor responder to CER, 
such as renal cell carcinoma and melanomas. Another 
potentially good clinical scenario for SRS is in cases in 
which CER has failed to achieve local disease control.
CONCLUSION
SRS can be used for the treatment of epidural spinal 
metastases (level II of evidence) and spinal myeloma 
(level III), especially in tumors known to be poor 
responders to CER (such as melanoma or renal cell 
carcinoma) (level III). SRS is also indicated for salvage 
treatment when CER fails to control disease (level II), 
as reirradiation of patients without any other potential 
treatment available. There is some evidence (level III) 
of the efficacy and safety of SRS in the treatment of 
intradural extramedullary and intramedullary spinal 
metastases. The same is true for its use after surgical 
procedures for canal decompression and stabilization 
(level III). Further prospective studies are necessary to 
compare the potential benefits of SRS over CER. 
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